A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
← catalyst calendarNCT06471829 · readout in 27 d
Sponsored by H. Lundbeck A/S (industry) · HLUN-B.CO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18estimated
Sites
27
Countries
France, Georgia, Hungary +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-19 | actual | When the study began enrolling |
| Primary completion | 2026-09-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cushing's Disease
Intervention
- Drug: Lu AG13909
Primary outcome
what the primary-completion date above is the date OFPart A & Part B: Urinary Free Cortisol (UFC) Complete Response: mean UFC (mUFC) ≤ Upper Limit of Normal (ULN) at the end of the IV/SC Titration Period
measured Up to 490 days
Permalink · HLUN-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed